Tuesday 16 June 2020
Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).
Yourgene Health (YGEN.LSE)
Collaboration in COVID-19 testing
Yourgene, a leading international molecular diagnostics group, announced a collaboration agreement with international payments company Caxton and immunity passport app Prova, which once launched will support the efforts to get Britain back to work by testing employees for COVID-19.
The collaboration with Prova and Yourgene will enable Caxton to offer COVID-19 tests to its extensive network of corporate clients and their employees. The immunity passport app Prova, created by London-based Hooha Innovations, enables employees to download and request a COVID-19 test. Once a test sample has been taken and the sample processed, the results will be automatically delivered securely to the Prova app, allowing the user to share and prove their COVID-19 status without revealing any personal information.
Yourgene's responsibilities will lie in providing the clinical and technical expertise, by providing sample collection kits, training a healthcare professional to take the sample safely and effectively then running the COVID-19 test in its Manchester Citylab facility. The collaboration will use the Company's ClarigeneTMSARS CoV-2 CE-IVD assay when launched and the patient results will be uploaded securely to the Prova app.
As announced on the 26 May 2020, the Company is still on track to release a 'Research Use Only' version of Clarigene SARS-CoV-2 test by the end of June 2020 and achieve a CE marked in vitro diagnostic kit to follow in July 2020.
Amiad Water Systems (AFS.LSE)
Amiad signs new five-year distribution agreement with Netafim
Amiad, a leading global producer of water treatment and filtration solutions, announced that it has signed a new five-year global distribution agreement with Netafim, the global leader in precision irrigation solutions, for the Company's disc filtration products for the irrigation market. This new agreement extends the existing long-term strategic relationship between the two companies.
Netafim is a leading manufacturer and distributer of precision irrigation solutions and the world's largest irrigation company. Under the terms of the new agreement, which commences 1 January 2021 (following the expiry of the current agreement at the end of this year), Netafim will have exclusive distribution rights to Amiad's well known disc filtration products in the irrigation market globally and to Amiad's screen filtration products in the Netherlands, subject to continuing to meet certain sales thresholds.
This agreement provides Amiad with continued access to Netafim's extensive distribution network, covering over 110 countries, which represents an important contributor to the Company's sales in the irrigation market.
or full RNS details, see: https://www.investegate.co.uk/amiad-water-systems--afs-/rns/new-five-year-agreement-with-netafim/202006160700030337Q/
Faron Pharma (FARN.LSE)
Faron update on pipeline progress ahead of R&D Day
Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today provided an update on the progress of its two clinical stage programmes, Clevegen and Traumakine, ahead of the Company's virtual R&D Day.
Clevegen is Faron's wholly-owned novel precision cancer immunotherapy, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. Faron today announces that:
The World Health Organization (WHO) has approved bexmarilimab as the International Nonproprietary Name (INN) for Clevegen.
An additional cohort has been added to Part II of the ongoing MATINS trial, exploring the potential of bexmarilimab in patients with anaplastic thyroid cancer, currently without effective treatment. This follows announcement by the Company on 30 March 2020 of the cancer types to be included in Part II of the trial.
Clinical expansion plans for bexmarilimab will include the investigation of alternative dosing cycles, as pharmacodynamics markers may indicate a need for shorter frequencies, as well as further studies in additional clinical settings.
Clinical studies are being planned to investigate bexmarilimab in combination with standard of care (SOC) as a first-line therapy in selected advanced solid tumours, and as a standalone neoadjuvant therapy for patients with early stage colon cancer. The Company currently expects patient recruitment for a small number of cohorts to complete around late Q3 with discussions with the FDA to follow in Q4.
Traumakine, Faron's investigational intravenous (IV) interferon (IFN) beta-1a, is currently under development for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS) and is being used in two global, adaptive trials investigating potential COVID-19 treatments - REMAP-CAP, the Randomized, Embedded, Multifactorial Adaptive Platform rial for Community-Acquired Pneumonia, and the WHO Solidarity trial.
Today the Company announces that a third trial will investigate the potential of Faron's IV IFN beta-1a to treat COVID-19. HIBISCUS (Human Interferon Beta In Severe CoronavirUS), will be an investigator initiated study at Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC), focused on ICU patients with ARDS caused by viral infection (e.g. COVID-19, influenza). The phase II/III pivotal, randomized, placebo controlled study aims to recruit 350 patients with 1:1 randomization who will be followed for ventilation free dats (VFD) and mortality over the 28 day period post first dosing. No corticosteroid use will be accepted in the study which is expected to enroll patients over 6-8 months throughout the US with many significant hospitals participating. Commencement of the trial remains subject to finalisation of funding arrangements and regulatory approval. Further announcements will be made in due course.